Ligand Pharmaceuticals (LGND) EBITDA (2010 - 2026)
Ligand Pharmaceuticals (LGND) EBITDA from Jun 30, 2010 to Mar 31, 2026. The TTM Ligand Pharmaceuticals (LGND) EBITDA is $128M. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual EBITDA
Quarterly EBITDA
Ligand Pharmaceuticals (LGND) EBITDA CAGR table
| Period | CAGR |
|---|---|
| 3 Years TTM | +26.94% |
| 5 Years TTM | +11.77% |
| 10 Years TTM | +11.35% |
Annual EBITDA change of Ligand Pharmaceuticals (LGND)
| Year | EBITDA | Change |
|---|---|---|
| 2026 | $26M | -65.79% |
| 2025 | $75M | +492.08% |
| 2024 | $13M | -73.94% |
| 2023 | $48M | -11.20% |
| 2022 | $55M | -64.78% |
| 2021 | $155M | +145.17% |
| 2020 | $63M | -92.34% |
| 2019 | $825M | +367.64% |
| 2018 | $177M | +123.35% |
| 2017 | $79M | +43.22% |
| 2016 | $55M | +84.18% |
| 2015 | $30M | +34.47% |
| 2014 | $22M | +26.52% |
| 2013 | $18M | +503.08% |
| 2012 | $2.92M | +39.71% |
| 2011 | $2.09M | -107.72% |
| 2010 | -$27M | +408.26% |
| 2009 | -$5.33M | N/A |
Comparison Ligand Pharmaceuticals (LGND) five years EBITDA CAGR with competitors
Ligand Pharmaceuticals (LGND) five years EBITDA CAGR is 11.77%.